368 related articles for article (PubMed ID: 25477010)
1. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
2. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Mizusawa J; Morizane C; Okusaka T; Katayama H; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2016 Apr; 46(4):385-8. PubMed ID: 27025903
[TBL] [Abstract][Full Text] [Related]
5. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Valle JW; Wasan H; Lopes A; Backen AC; Palmer DH; Morris K; Duggan M; Cunningham D; Anthoney DA; Corrie P; Madhusudan S; Maraveyas A; Ross PJ; Waters JS; Steward WP; Rees C; Beare S; Dive C; Bridgewater JA
Lancet Oncol; 2015 Aug; 16(8):967-78. PubMed ID: 26179201
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
Bridgewater J; Lopes A; Beare S; Duggan M; Lee D; Ricamara M; McEntee D; Sukumaran A; Wasan H; Valle JW
BMC Cancer; 2016 Feb; 16():153. PubMed ID: 26912134
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
Toyoda M; Ajiki T; Fujiwara Y; Nagano H; Kobayashi S; Sakai D; Hatano E; Kanai M; Nakamori S; Miyamoto A; Tsuji A; Kaihara S; Ikoma H; Takemura S; Toyokawa H; Terajima H; Morita S; Ioka T
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1295-301. PubMed ID: 24614947
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
[TBL] [Abstract][Full Text] [Related]
9. A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
McNamara MG; Bridgewater J; Palmer DH; Faluyi O; Wasan H; Patel A; Ryder WD; Barber S; Gnanaranjan C; Ghazaly E; Evans TRJ; Valle JW
Oncologist; 2021 Apr; 26(4):e669-e678. PubMed ID: 33210382
[TBL] [Abstract][Full Text] [Related]
10. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; Sottotetti E; Martinetti A; Busset MDD; Sposito C; Di Bartolomeo M; Pietrantonio F; de Braud F; Mazzaferro V
BMC Cancer; 2024 Apr; 24(1):436. PubMed ID: 38589856
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
Fiteni F; Nguyen T; Vernerey D; Paillard MJ; Kim S; Demarchi M; Fein F; Borg C; Bonnetain F; Pivot X
Cancer Med; 2014 Dec; 3(6):1502-11. PubMed ID: 25111859
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04).
Shimoyama R; Imamura Y; Uryu K; Mase T; Taguri M; Okuda T; Fujimura Y; Hayashi M; Tanaka S; Sawamukai K; Minami H
Jpn J Clin Oncol; 2024 Jan; 54(1):70-80. PubMed ID: 37801431
[TBL] [Abstract][Full Text] [Related]
13. NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).
McNamara MG; Goyal L; Doherty M; Springfeld C; Cosgrove D; Sjoquist KM; Park JO; Verdaguer H; Braconi C; Ross PJ; Gramont A; Zalcberg JR; Palmer DH; Valle JW; Knox JJ
Future Oncol; 2020 Jun; 16(16):1069-1081. PubMed ID: 32374623
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M; Morizane C; Furukawa M; Sakai D; Komatsu Y; Nakai Y; Tsuda M; Ozaka M; Mizuno N; Muto M; Fukutomi A; Ikeda M; Tsuji A; Katanuma A; Moriwaki T; Kajiwara T; Ishii H; Negoro Y; Shimizu S; Nemoto N; Kobayashi S; Makino K; Furuse J
Cancer Med; 2021 Mar; 10(6):2088-2099. PubMed ID: 33635605
[TBL] [Abstract][Full Text] [Related]
15. Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04).
Mohan A; Griffith KA; Wuchu F; Zhen DB; Kumar-Sinha C; Crysler O; Hsiehchen D; Enzler T; Dippman D; Gunchick V; Achreja A; Animasahun O; Choppara S; Nenwani M; Chinnaiyan AM; Nagrath D; Zalupski MM; Sahai V
Clin Cancer Res; 2023 Jul; 29(13):2394-2400. PubMed ID: 37115501
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for biliary tract cancer: real-world experience in a single institute.
Maeda O; Ebata T; Shimokata T; Matsuoka A; Inada-Inoue M; Morita S; Takano Y; Urakawa H; Miyai Y; Sugishita M; Mitsuma A; Ando M; Mizuno T; Nagino M; Ando Y
Nagoya J Med Sci; 2020 Nov; 82(4):725-733. PubMed ID: 33311803
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.
Valle JW; Wasan H; Johnson P; Jones E; Dixon L; Swindell R; Baka S; Maraveyas A; Corrie P; Falk S; Gollins S; Lofts F; Evans L; Meyer T; Anthoney A; Iveson T; Highley M; Osborne R; Bridgewater J
Br J Cancer; 2009 Aug; 101(4):621-7. PubMed ID: 19672264
[TBL] [Abstract][Full Text] [Related]
18. Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.
Milella M; Gelibter AJ; Pino MS; Bossone G; Marolla P; Sperduti I; Cognetti F
Oncologist; 2010; 15(2):e1-4. PubMed ID: 20189980
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ; Christos P; Sparano JA; Matulich D; Kaubish A; Siegel A; Sung M; Ward MM; Hamel N; Espinoza-Delgado I; Yen Y; Lane ME
Cancer Chemother Pharmacol; 2011 Aug; 68(2):379-88. PubMed ID: 20981545
[TBL] [Abstract][Full Text] [Related]
20. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ; Fan J; Oh DY; Choi HJ; Kim JW; Chang HM; Bao L; Sun HC; Macarulla T; Xie F; Metges JP; Ying J; Bridgewater J; Lee MA; Tejani MA; Chen EY; Kim DU; Wasan H; Ducreux M; Bao Y; Boyken L; Ma J; Garfin P; Pant S;
Lancet Oncol; 2023 Jul; 24(7):772-782. PubMed ID: 37276871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
